Company news

Dogwood Therapeutics, Inc. news in 2021

Dogwood Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia

November 30, 2021

Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update

November 10, 2021

Virios Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Thursday, November 11, 2021

November 3, 2021

Virios Therapeutics Granted New Patent for Antiviral Inhibitor Combination

September 7, 2021

Virios Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 1, 2021

Virios Therapeutics Announces New Social Media Profiles

August 18, 2021

Virios Therapeutics Announces Second Quarter 2021 Financial Results and Provides Corporate Update

August 11, 2021

Virios Therapeutics to Present at the SNN Network Summer Virtual Conference

August 10, 2021

Virios Therapeutics Featured in Bloomberg TV Interview

August 8, 2021

Virios Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Thursday, August 12, 2021

August 4, 2021

Virios Therapeutics Highlights Clinical Sites Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA “Fast Track” Review Designated Antiviral Therapy, Oral IMC-1

July 25, 2021

Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World Congress

June 8, 2021

Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia

June 3, 2021

Calls in 2021

Decks in 2021